621 reports of this reaction
3.1% of all TOBRAMYCIN SOLUTION reports
#5 most reported adverse reaction
DYSPNOEA is the #5 most commonly reported adverse reaction for TOBRAMYCIN SOLUTION, manufactured by Amneal Pharmaceuticals LLC. There are 621 FDA adverse event reports linking TOBRAMYCIN SOLUTION to DYSPNOEA. This represents approximately 3.1% of all 19,799 adverse event reports for this drug.
Patients taking TOBRAMYCIN SOLUTION who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among TOBRAMYCIN SOLUTION users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for TOBRAMYCIN SOLUTION:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 621 FDA reports for TOBRAMYCIN SOLUTION. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.1% of all adverse event reports for TOBRAMYCIN SOLUTION, making it a notable side effect.
If you experience dyspnoea while taking TOBRAMYCIN SOLUTION, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.